Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CTEVthis companyClaritev Corporation	$24.06	-2.47×	-4.04×	0.73×	11.19×	412.8%	27.6%	4.7%	-29.4%	163.5%	0.7%	-1.7%	-26.64×	9.71×	0.11×	0.86×	0.0%	5	-0.44	2	C
AXGNAxoGen, Inc.	$50.40	-96.26×	11.7×	6.69×	8,017.22×	-145.4%	74.3%	-3.5%	-7.0%	-12.2%	-3.9%	-0.2%	0.52×	167.09×	-1.02×	5.11×	0.0%	4	33.22	2	C
DNTHDianthus Therapeutics, Inc.	$89.26	-9.81×	3.16×	764.98×	-9.31×	-101.9%	100.0%	-8739.3%	-7973.3%	-32.9%	-35.5%	-8.3%	0×	0.31×	0×	13.32×	0.0%	1	67.2	2	C
EVHEvolent Health, Inc.	$4.54	-0.79×	1.1×	0.24×	-3.58×	-2363.6%	15.1%	-0.2%	-28.5%	-128.7%	-0.3%	1.0%	2.38×	-2.32×	-0.08×	1.31×	2.4%	5	-0.38	2	C+
GDRXGoodRx Holdings, Inc.	$3.58	31.73×	1.57×	1.21×	6.76×	43.7%	92.8%	11.0%	3.8%	4.9%	4.0%	17.0%	0.88×	1.52×	2.05×	2.61×	0.0%	7	0.27	3	B-
IARTIntegra LifeSciences Holdings Corporation	$13.61	-1.85×	0.91×	0.58×	-8.46×	77.8%	51.7%	4.2%	-31.6%	-49.5%	1.9%	-4.7%	1.95×	-5.53×	0.79×	2.54×	0.0%	7	1.31	3	B
Peer median	—	-1.85×	1.57×	1.21×	-3.58×	-101.9%	74.3%	-0.2%	-28.5%	-32.9%	-0.3%	-0.2%	0.88×	0.31×	0×	2.61×	0.0%	5	1.31	2	—